CASEY SALCEDO: Open Payments
NPI 1699324707 · ROYSTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,547 in 96 payments from 18 companies in 2025. Trend: 2023 $925 · 2024 $1,170 · 2025 $1,547
Food & beverage: $1,547
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $247 |
| ABBVIE INC. | 17 | $219 |
| Novo Nordisk Inc | 13 | $214 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $138 |
| Axsome Therapeutics, Inc. | 11 | $138 |
| AstraZeneca Pharmaceuticals LP | 4 | $77 |
| Amgen Inc. | 4 | $73 |
| GlaxoSmithKline, LLC. | 3 | $70 |
| Lilly USA, LLC | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
Products named: REXULTI, UBRELVY, CAPLYTA, Auvelity, Ozempic, TRELEGY ELLIPTA, MOUNJARO, TRINTELLIX.
Industry payments across GA — which companies pay providers there.
